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The development of factor VIII (FVIII) inhibitors is the major complication of replacement 
therapy in patients with severe hemophilia A (HA). Experimental and clinical evidence 
suggest that the presence of exogenous von Willebrand factor (VWF) in FVIII products 
reduces the immunogenicity of therapeutic FVIII.1-3 However, a direct immuno-protective 
effect of endogenous VWF remains unclear.4, 5 The binding of VWF to FVIII implicates the 
first 272 amino acids of the mature VWF (D’-D3 region) encoded by the exons 18-23 of the 
VWF gene.6 Mutations in the VWF gene that result in quantitative or qualitative defects in 
VWF lead to von Willebrand disease (VWD). Polymorphisms in the VWF gene were studied 
in the context of venous thrombosis and VWD,7, 8 but, to our knowledge, not in that of HA. 
Here, we investigated whether the capacity of endogenous VWF in patients with severe HA to 
modulate inhibitor development depends on its capacity to bind to therapeutic FVIII. Our 
working hypothesis was that gene variations in the D’-D3 region result in qualitative changes 
in the capacity of circulating endogenous VWF to bind FVIII. While such polymorphisms do 
not translate into coagulation abnormalities, they might have an impact on the stabilization of 
the therapeutically administered exogenous FVIII in patient with HA. The consequence would 
be an increased ratio of free versus bound FVIII molecules and a potentially reduced immuno-
protection of FVIII by VWF. Our result show that the relative binding of endogenous VWF to 
therapeutic FVIII is a poor predictor of inhibitor development, probably reflecting the multi-
causal nature of the inhibitor risk.9, 10 
We first evaluated the capacity of endogenous VWF in the plasma of 48 randomly selected 
patients with severe HA to bind rFVIII in vitro. VWF:Ag levels were 89.8% (standard error 
mean (SEM) 10.4) and 91.9% (SEM 13.0) for inhibitor-positive and inhibitor-negative 
patients, respectively (95% CI -30.9 to 35.0). The relative VWF binding to FVIII (referred to 
as VWF:FVIIIB) was determined in each sample using an immuno-assay initially validated 
for the diagnosis of type 2N VWD (See Methods in supplement). VWF:FVIIIB was normally 
distributed and ranged between 41.1% and 158.9%. Interestingly, the distribution of 
VWF:FVIIIB was different for inhibitor-positive and negative patients (Figure 1A) with 
means of 86.4% (SEM 5.1) for inhibitor-positive patients as opposed to 103.6% (SEM 5.8) 
for inhibitor-negative patients (95% CI 1.3-33.2). The ROC curve of VWF:FVIIIB as a 
predictor of inhibitor development in patients with severe HA yielded an area under the curve 
of 0.668 (95% CI 0.513-0.821, Figure 1B). Upon examination of the coordinates of the ROC 
curve, we chose a potential VWF:FVIIIB cut-off value of 95% that yielded the best relation 
between sensitivity and specificity. Using this cut-off value, a VWF:FVIIIB below 95% was 
more frequent among inhibitor-positive patients than inhibitor-negative patients (71% versus 
37%), and a value below this cut-off was associated with an over fourfold increased risk of 
inhibitor development (odds ratio 4.3, 95% CI 1.3-14.5). The proposed cut-off value exhibited 
a sensitivity of 0.71 (95% CI 0.48-0.89) and specificity of 0.63 (95% CI 0.42-0.81). The 
calculated positive and negative predictive values (PPV and NPV) for the prediction of 
inhibitor development were 0.4 and 0.83, respectively, using an inhibitor prevalence of 30%. 
These data suggest the potential of the VWF:FVIIIB assay in the preventive identification of 
severe HA patients at a low risk of developing inhibitors during FVIII replacement therapy. It 
is noteworthy, however, that a substantial number (38%) of the inhibitor-negative patients 
included in the study had VWF:FVIIIB scores lower than the median of the whole population; 
conversely, 35% of the inhibitor-positive patients presented with VWF:FVIIIB scores greater 
than the median. These results highlight the multi-causal nature of inhibitor development. 
Exons 18 to 23 were directly sequenced in order to characterize Single Nucleotide 
Polymorphisms (SNP) in the VWF gene from the 48 patients previously tested for 
VWF:FVIIIB (See Supplementary Methods). Four SNPs were identified with a prevalence 
equivalent to that previously described in different non-hemophilic populations8: c.2365 
A>G, p.Thr789Ala (rs1063856); c.2385 T>C, p.Tyr795Tyr (rs1063857); c.2555 G>A, 
p.Arg852Gln (rs216321) and c.2880 G>A, p.Arg960Arg (rs1800380). The association 
between VWF:FVIIIB and SNP genotypes was assessed. The two silent SNPs (p.Tyr795Tyr 
and p.Arg960Arg) (data not shown) and the p.Thr789Ala had no impact on VWF:FVIIIB 
(Figure 1C). However, c.2555 G>A SNP, corresponding to the substitution of an arginine 
with a glutamine at position 852, was associated with a statistically significant reduction in 
VWF:FVIIIB in the case of plasma from the heterozygous G/A patients as compared to 
plasma from patients with the homozygous frequent G/G genotype (P<0.001, 95% CI 11.87-
42.51) (Figure 1D). No patient with the rare A/A genotype was detected. Two patients carried 
either one of the p.Arg854Gln and p.Arg924Gln mutations associated with VWD. The 
transition p.Arg854Gln, described as a type 2N VWD causative mutation,11 was found in one 
patients without inhibitor. Previously reported to be a polymorphism in a study of type 2N 
VWD mutations,12 the p.Arg924Gln, which represents a non-conservative amino acid 
substitution in exon 21, was observed in one patient with inhibitor. These missense mutations 
were associated with normal VWF:Ag levels and reduced VWF:FVIIIB, 41% and 42% in one 
inhibitor-negative patient and one inhibitor-positive patient, respectively (lower 2 points in 
Figure 1D). A previous study by Nesbitt et al. had identified the c.2555 G>A SNP in 16 of 
148 screened alleles.13 In contrast to our findings, their results had suggested that the 
VWF:FVIIIIB was not affected by the p.Arg852Gln polymorphism in VWF, possibly owing 
to the relatively low number of patients with the c.2555 G>A SNP included in their study. 
In an attempt to determine whether the c.2555 G>A SNP in exon 18 of the VWF gene is 
associated with the occurrence of FVIII inhibitors in the patients, we searched for the SNP in 
235 patients enrolled in the SIPPET study.2 The cohort included 163 inhibitor-negative 
patients and 72 inhibitor-positive patients, encompassing 14 low-responder and 48 high-
responder patients. Genotype frequencies of the polymorphism are summarized in Table 1. 
The distribution of the c.2555 G>A genotypes did not deviate from the Hardy-Weinberg 
equilibrium in both inhibitor-negative and inhibitor-positive patients. No clear association 
between the c.2555 G>A SNP genotypes and the development of inhibitors was observed 
(Table 1, OR 0.61, 95% CI 0.28-1.32). These data are in line with a similar analysis 
performed in parallel using biological samples from a multicentric retrospective cohort of 281 
patients with severe HA14 (supplementary Tables S1 and S2), suggesting that the different 
ethnic origin of patients in the SIPPET cohort2 does not account for the results. Genotypes 
and alleles frequencies in both cohorts were identical to results from the 1000 Genomes 
Project (1111G).8  
If our working hypothesis is correct, the nature of the VWF variant should play a role 
predominantly for patients receiving rFVIII products, but not for patients receiving exogenous 
VWF with the pdFVIII products. Among the 235 SIPPET patients included in the present 
study, 118 patients were treated with rFVIII concentrates and 117 patients received pdFVIII 
products following randomization (1:1). Associations between the genotype distribution and 
development of FVIII inhibitors were addressed in the two groups of patients (Table 1). There 
was again no clear association between the presence of A allele of the c.2555 G>A SNP and 
the presence of a FVIII inhibitor, both in the case of the rFVIII-treated group (OR 1.16, 95% 
CI 0.41-3.30) and of the pdFVIII-treated patients (OR 0.12, 95% CI 0.09-1.24). A genome-
wide association study evaluated 13331 SNPs from 1,081 genes using the Illumina iSelect 
platform for associations with inhibitor development in patients with HA. The study group 
included 833 subjects from three independent cohorts. The authors identified 53 SNPs as 
significant predictors of the inhibitor status, thus highlighting the complexity of the anti-FVIII 
immune response.15 However, the genome-wide association study did not find associations of 
SNPs in the VWF gene with the inhibitor status of the patients, which comforts the present 
findings. 
A major limitation of the study is the discrepancy between our observations: i) an overall 
reduced relative endogenous VWF binding endogenous VWF in the plasma from inhibitor-
positive severe HA patients, ii) a reduced relative endogenous VWF binding with the c.2555 
G>A SNP and iii) the lack of association of the 2555 G>A SNP with the inhibitory status of 
the patients. Recently, Muczynski et al. developed a recombinant FVIII (FVIII-KB013bv) that 
contains two VWF-specific nanobodies in place of the B domain.16 FVIII-KB013bv has a 25-
fold increased affinity for VWF as compared to B domain-deleted FVIII, and exhibits a 
prolonged blood residence time in FVIII-deficient mice. Interestingly, FVIII-KB013bv 
demonstrated an almost complete lack of immunogenicity in vivo in FVIII-deficient mice. In 
view of the latter information, the discrepancy between our observations may be explained by 
the fact that, owing to the multi-causal nature of the inhibitor risk, an affinity of the 
endogenous VWF for therapeutic FVIII in the high physiological range does not 
systematically play a major protective role. Instead, a stabilization of the complex beyond the 
physiological equilibrium affinity is required to exert blatant immune-protective functions.  
 
Acknowledgements 
The work was supported by Institut National de la Santé et de la Recherche Médicale 
(INSERM), Centre National de la Recherche Scientifique (CNRS), Université Paris 
Sorbonne, and Agence Nationale de la Recherche (ANR-07-MRAR-028-01).  
†This work is dedicated to the memory of our late colleague and friend Catherine Costa, an 
extraordinary geneticist and a wonderful human being.  
 
Authors contribution  
Designed research: YR, SVK, SLD 
Performed research: YR, CC, RP, EFM, AP, SLD 
Participated to cohorts: CC, ABD, Rd’O, CR, AEB, ME, VR, PE, JO, PMM, FRR, FP 
Analyzed data: YR, RP, FP, SLD 
Wrote the paper: YR, RP, FP, SLD 
The authors declare no conflict of interest 
 
Appendix 
SIPPET Study Group. S. Hanagavadi, Davangere, India; R. Varadarajan, Chennai, India; M. 
Karimi, Shiraz, Iran; M. V. Manglani, Mumbai, India; C. Ross, Bangalore, India; G. Young, 
Los Angeles, USA; T. Seth, New Delhi, S. Apte, Pune, India; D. M. Nayak, Karnataka, India; 
E. Santagostino, M. Elisa Mancuso, Milan, Italy; A. C. Sandoval Gonzalez, Monterrey, 
Mexico; J. N. Mahlangu, Johannesburg, South Africa; S. Bonanad Boix, Valencia, Spain; M. 
Cerqueira, Rio de Janeiro, Brazil; N. P. Ewing, Duarte, USA; C. Male, Vienna, Austria; T. 
Owaidah, Riyadh, Saudi Arabia; V. Soto Arellano, Fargo, USA; N. L. Kobrinsky, Jackson, 
USA; S. Majumdar, R. Perez Garrido, Sevilla, Spain; A. Sachdeva, New Delhi, India; M. 
Simpson, Chicago, USA; M. Thomas, Kerala, India; E. Zanon, Padova, Italy; B. Antmen, 
Adana, Turkey; K. Kavakl, Izmir, Turkey; M. J. Manco-Johnson, Aurora, USA;M. Martinez, 
Buenos Aires, Argentina; E. Marzouka, Santiago, Chile; M. G. Mazzucconi, Rome, Italy; D. 
Neme, Buenos Aires, Argentina; A. Palomo Bravo, Malaga, Spain; R. Paredes Aguilera, 
M_exico City, Mexico; A. Prezotti, Vitoria, Brazil; K. Schmitt, Linz, Austria; B. M. 
Wicklund, Kansas City, USA; B. Zulfikar, Istanbul, Turkey. 
 
References 
1. Lai J, Hough C, Tarrant J, Lillicrap D. Biological considerations of plasma-derived and 
recombinant factor VIII immunogenicity. Blood. 2017;129(24):3147-3154. 
2. Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor VIII and 
Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374(21):2054-2064. 
3. Calvez T, Chambost H, d'Oiron R, et al. Analyses of the FranceCoag cohort support 
differences in immunogenicity among one plasma-derived and two recombinant factor 
VIII brands in boys with severe hemophilia A. Haematologica. 2018;103(1):179-189. 
4. Gangadharan B, Ing M, Delignat S, et al. The C1 and C2 domains of blood coagulation 
factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017;102(2):271-
281. 
5. Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of 
factor VIII in a murine model is independent of its procoagulant function. Blood. 
2012;120(12):2512-2520. 
6. Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction 
between human blood-coagulation factor VIII and von Willebrand factor. Biochem J. 
1989;257:679-683. 
7. Bittar LF, de Paula EV, Mello TB, et al. Polymorphisms and mutations in vWF and 
ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients 
with deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17(5):514-518. 
8. Wang QY, Song J, Gibbs RA, et al. Characterizing polymorphisms and allelic diversity 
of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost. 
2013;11(2):261-269. 
9. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in 
hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35(8):723-734. 
10. Eckhardt CL, van Velzen AS, Fijnvandraat CJ, van der Bom JG. Dissecting intensive 
treatment as risk factor for inhibitor development in haemophilia. Haemophilia. 
2016;22(3):e241-244. 
11. Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C. Identification of two point 
mutations in the von Willebrand factor gene of three families with the 'Normandy' variant 
of von Willebrand disease. Br J Haematol. 1991;78(4):506-514. 
12. Hilbert L, Jorieux S, Proulle V, et al. Two novel mutations, Q1053H and C1060R, 
located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-
binding capacity. Br J Haematol. 2003;120(4):627-632. 
13. Nesbitt IM, Goodeve AC, Preston FE, Peake IR. von Willebrand factor/factor VIII 
binding is not affected by the Arg89Gln polymorphism in von Willebrand factor. Thromb 
Haemost. 1996;76(5):820-821. 
14. Repesse Y, Peyron I, Dimitrov JD, et al. Development of inhibitory antibodies to 
therapeutic factor VIII in severe hemophilia A is associated with microsatellite 
polymorphisms in the HMOX1 promoter. Haematologica. 2013;98(10):1650-1655. 
15. Astermark J, Donfield SM, Gomperts ED, et al. The polygenic nature of inhibitors in 
hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined 
Cohort. Blood. 2013;121(8):1446-1454. 
16. Muczynski V, Casari C, Moreau F, et al. A factor VIII-nanobody fusion protein forming 
an ultrastable complex with VWF: effect on clearance and antibody formation. Blood. 
2018;132(11):1193-1197. 
 
Table 1. c.2555 G>A genotypes distribution and association with the development of FVIII inhibitor in 235 patients 
with severe HA from the SIPPET study2 
 
    
rFVIII + pdFVIII Inh-negative (n=163) Inh-positive (n=72)   
  LR (n=24) HR (n=48) LR+HR (n=72) OR 95% CI 
G/G 129 (79%) 22 40 62 (86%) 
0.61 0.28-1.32 
G/A + A/A 34 (21%) 2 8 10 (14%) 
    
rFVIII-treated group Inh-negative (n=73) Inh-positive (n=45)   
  LR (n=16) HR (n=29) LR+HR (n=45) OR 95% CI 
G/G 63 (86%) 15 23 38 (84%) 
1.16 0.41-3.30 
G/A + A/A 10 (14%) 1 6 7  (16%) 
    
pdFVIII-treated group Inh-negative (n=90) Inh-positive (n=27)   
  LR  (n=8) HR (n=19) LR+HR (n=27) OR 95% CI 
G/G 66 (73%) 7 17 24 (89%) 
0.35 0.09-1.24 
G/A + A/A 24 (27%) 1 2 3 (11%) 
LR: Low Responder; HR: High Responder; CI: confidence interval; OR: Odds Ratio. 
 
Figure Legend 
 
Figure 1. Relative endogenous VWF binding and inhibitory status in patients with 
severe HA. Panel A. Association between relative VWF binding (VWF:FVIIIB) and inhibitor 
status in severe HA patients (n=48). The X axis represents the inhibitor status: patients with 
HA without FVIII inhibitor (Inh-neg) and with FVIII inhibitor (Inh-pos). The Y axis 
represents the relative binding of recombinant FVIII to the endogenous VWF in the plasma of 
patients with severe HA measured by ELISA (expressed in %). The 95% confidence intervals 
(CI) was constructed with the standard errors derived from the Student’s t distribution. Panel 
B. Receiver Operating Characteristic (ROC) curve for predicting inhibitor development in 
patients with severe HA by measurement of VWF:FVIIIB. The true positive rate (sensitivity) 
is plotted as a function of the false positive rate (100-specificity). AUC, Area Under Curve. 
Panels C and D. Association between VWF:FVIIIB and the p.Thr789Ala (c.2365 A>G) 
polymorphism (C) or the p.Arg852Gln (c.2555 G>A) polymorphism (D) in the exon 18 of the 
VWF gene. Statistical difference were determined using the Student’s t test.  
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Supplementary file 
Supplementary Methods 
Plasma samples 
Plasma samples were obtained from frozen citrated plasma of 21 randomly selected inhibitor-
positive and of 27 randomly selected inhibitor-negative patients (mean age 26 years; range 3-
72) with severe hemophilia A (FVIII:C<0.01 UI/mL) treated with recombinant FVIII 
concentrates. Plasma had been collected during the usual clinical follow-up of patients with 
severe hemophilia A between 2008 and 2009 from hemophilia centers in France (Hôpital de 
Caen, Hôpital de Bicêtre) and Germany (University Clinic Bonn) and were analyzed in 2009. 
Approval for these studies was obtained from the Caen University institutional review board 
(Ethical committee agreement reference A16-D02-VOL.27). Written informed consent was 
provided by each patient according to the Declaration of Helsinki. Patients who had never 
developed an inhibitor after 150 cumulative exposure days (CED) or more were defined as 
inhibitor-negative patients. Inhibitor historical peak titers were documented for 20 of the 21 
inhibitor-positive patients (mean 9.2; range 2-5000). 
 
Randomized cohort of previously untreated patients with severe HA (SIPPET cohort) 
All patients analyzed in this study were previously untreated or minimally-treated patients with 
severe HA enrolled in the multicenter, randomized, open-label clinical trial named SIPPET.1 
Patients included in SIPPET were randomized 1:1 to receive either plasma-derived FVIII 
(pdFVIII) or recombinant FVIII (rFVIII) and followed up for inhibitor development for 50 
exposure days (EDs) or three years. Inclusion criteria included a severe deficiency of FVIII 
(FVIII:C <0.01 IU/mL) and the absence of FVIII inhibitor. Of the 251 patients enrolled in the 
SIPPET study, DNA samples were available from 235 patients (118 treated with rFVIII and 
117 treated with pdFVIII) for analysis in VWF gene as per the original protocol 
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(ClinicalTrials.gov number, NCT01064284; EudraCT number, 2009-011186-88). Contributing 
centers to the SIPPET study group are listed in the Appendix.  
 
Multicentric retrospective cohort 
A multicentric retrospective cohort was constituted that included 281 patients with severe 
hemophilia A from different hemophilia centers in France (Hôpital de Caen, Hôpital de Bicêtre) 
and Germany (University Clinic Bonn). The cohort has been described previously.2 The 
selection criterion was severe hemophilia A (FVIII:C<0.01 UI/mL). Inhibitor-negative patients 
(n=212) were defined as patients who had never developed an inhibitor after ≥150 cumulative 
exposure days (CED). Sixty-nine patients had been diagnosed with a FVIII inhibitor. Inhibitor 
historical peak titers were documented for 63 of the 69 inhibitor-positive patients: 20 patients 
had a historical peak titer <5 Bethesda units (BU)/mL (mean 2.6; range 1.0–4.8) and 43 patients 
had a historical peak titer ≥5 BU/mL (mean 1430; range 5 – 50000). The 212 inhibitor-negative 
patients matched with the 69 inhibitor-positive patients for the type of hemophilia A-causing 
mutation, with the exception of missense mutations that were more frequent among inhibitor-
negative patients (Supplementary Table S1). Approval for this study was obtained from the 
Caen University institutional review board (ethical committee agreement reference A16-D02-
VOL.27). Written informed consent was provided by each patient according to the Declaration 
of Helsinki. 
 
Von Willebrand antigen (VWF:Ag) assay 
VWF:Ag was determined in patients’ plasma using the commercially available Asserachrom 
VWF:Ag assay (Stago®, Asnières, France), following the manufacturer’s recommendations. 
 
VWF-FVIII binding assay (VWF:FVIIIB) 
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The relative binding of plasma VWF to exogenous FVIII was measured using an enzyme-linked 
immunosorbent assay (ELISA) as previously described,3 with a slight modification. A 
microplate (Maxisorp, Nunc, Denmark) was coated by incubation for 24 hours at 2 to 8°C with 
5 µg/ml of rabbit polyclonal anti-human VWF IgG (A0082, Dako®, Copenhagen, Denmark) 
in 0.05 mmol/L carbonate buffer, pH 9,6. After washing with Tris 50 mmol/L, NaCl 100 
mmol/L (TBS) buffer containing 0.05% Tween 20, the wells were saturated with TBS 
containing 3% BSA for 1 hour at 37°C. Plasma samples were then incubated over night at 2 to 
8°C in the saturation buffer. Normal plasma (NP) (Standart Human Plasma, Siemens, Marburg, 
Germany) and dilutions of a mixture (vol/vol) of NP with the plasma of a type 2N VWD patient 
homozygous for the p.Arg854Gln mutation (NP/2N mixture) were also included in each assay. 
Each patient’s sample was tested in six serial dilutions, the first being adjusted to 0.05 IU/ml 
according to the VWF antigen (VWF:Ag) level. After removal of potential residual endogenous 
FVIII using 350 mmol/L CaCl2 (10 min, twice at room temperature), 100 mIU of therapeutic 
rFVIII (Helixate® NexGen, CSL-Behring) diluted in TBS buffer with 10 mM of CaCl2 were 
added to each well. After incubation (2 hours at 37°C) and washing with TBS buffer, bound 
FVIII was quantified using a mouse monoclonal anti-FVIII IgG (1 µg/mL) coupled to HRP 
directed to A2 domain (77IP52H7) of FVIII. After washing, captured VWF was quantified 
using 0.13 µg/mL of peroxidase-conjugated rabbit polyclonal anti-human VWF IgG (P0226, 
Dako®, Copenhagen, Denmark). The color was developed by addition of ortho- phenylene 
diamine dihydrochloride and the optical density (OD) was read at 490 nm. Two reference 
curves were established in parallel: for the quantification of immobilized VWF, 1:10 (10 mU) 
to 1:640 (0.156 mU) dilutions of NP were used; for the quantification of bound rFVIII, we 
added various amounts (2.23 to 143 mIU) of rFVIII to the wells in which VWF (1:5 dilution of 
NP) had been immobilized. For each plasma dilution, the values of bound rFVIII were plotted 
against the amount of immobilized VWF. The slopes of the obtained regression lines reflected 
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the relative VWF binding to FVIII (referred to as VWF:FVIIIB). The VWF:FVIIIB values are 
expressed in percentages compared with NP (100%).  
Importantly, addition of monoclonal human anti-FVIII IgG to NP prior to incubation with 
immobilized anti-VWF antibodies did not alter the binding of recombinant FVIII to VWF 
(supplemental Figure S1), thus validating that the presence of anti-FVIII antibodies in plasma 
samples from inhibitor-positive patients does not interfere with the binding of endogenous 
VWF with the coated polyclonal anti-VWF IgG. Furthermore, addition of 350 mmol/L CaCl2 
was sufficient to remove residual FVIII and FVIII-anti-FVIII IgG complex potentially 
associated with endogenous VWF as depicted in supplemental Figure S2.  
The VWF-FVIII binding assay is not designed for the measure of the binding constants 
(affinity) that govern the interaction between FVIII and VWF. It measures relative differences 
in VWF binding between different samples under identical conditions, thus eliminating the need 
for equilibrium conditions, and monitors global variations in FVIII-VWF interactions, 
independently from possible variations in association or dissociation constants.  
 
Analysis of exons 18 to 23 of VWF gene 
DNA was isolated using automated extraction kit. Exons 18 to 26 were amplified by PCR. 
Primer sequences are available on request. Reaction were carried out using 100 to 200 ng 
genomic DNA. Nucleotide sequencing was carried out using Sanger technique. All sequence 
changes were confirmed on both strands. The numbering of VWF mutations is based on the 
most recent recommendations of the ISTH Scientific and Standardization Subcommittee on von 
Willebrand factor. 
 
Statistical analysis 
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The 95% confidence intervals (CI) for associations between the VWF:FVIIIB and patients 
groups as well as polymorphisms in the exon 18 of the VWF gene, were constructed with the 
standard errors derived from the Student’s t distributions. A Receiving Operating Characteristic 
(ROC) curve was constructed to examine the predictive value of the VWF:FVIIIB on the 
development of FVIII inhibitors. Associations between groups and specific classes of allele, as 
well as genotypes were expressed as odds ratios (OR) and associated 95% CI. Statistical 
analyses were performed using GraphPad Prism software (La Jolla California, USA). 
 
Supplementary Results 
Exons 18 to 23 were directly sequenced in order to characterize Single Nucleotide 
Polymorphisms (SNP) in the D’-D3 region of the VWF gene from 281 severe patients with HA 
in the multicentric retrospective cohort. Supplementary table 1 describes the distribution of 
FVIII mutations in the cohort of patients. As previously reported, missense mutations were 
associated with a lower risk of inhibitor formation (supplementary Table S1).  
In an attempt to determine whether the c.2555 G>A SNP in exon 18 of the VWF gene is 
associated with the occurrence of FVIII inhibitors in the patients, we determined c.2555 G>A 
genotype frequencies. The retrospective cohort included 212 inhibitor-negative patients and 69 
inhibitor-positive patients. Genotype frequencies of the polymorphism are summarized in 
supplementary Table S2. The distribution of the c.2555 G>A genotypes did not deviate from 
the Hardy-Weinberg equilibrium for both inhibitor-negative and inhibitor-positive patients. No 
clear association between the c.2555 G>A SNP genotypes and the development of inhibitors 
was observed (OR 1.82, 95% CI 0.87-3.80). 
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Supplementary tables 
Supplementary Table S1. Distribution of FVIII mutations for 281 severe HA patients. 
 
Inhibitor-negative patients 
(n=212) 
Inhibitor-positive patients 
(n=69) 
  
  LR (n=20) HR (n=49) LR+HR (n=69) OR 95% CI 
Inversion of intron 22 106 (50%) 13 30 43 (62%) 0.6 0.35-1.06 
Inversion of intron 1 3 (1%) 0 1 1 (1%) 0.98 0.1-9.55 
Deletions/insertions 29 (14%) 3 6 9 (13%) 1.06 0.47-2.36 
Non-sens mutations 25 (12%) 1 8 9 (14%) 0.89 0.39-2.02 
Missense mutations 49 (23%) 5 4 7 (10%) 2.66 1.14-6.20 
LR: Low Responder; HR: High Responder; CI: confidence interval; OR: Odds Ratio 
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Supplementary Table S2. c.2555 G>A genotypes distribution and association with the development of FVIII 
inhibitor for 281 severe HA patients. 
 Inhibitor-negative (n=212) Inhibitor-positive (n=69) OR 95% CI 
G/G 188 (89%) 56 (81%) 
1.82 0.87-3.80 
G/A + A/A 24 (11%) 13 (19%) 
CI: confidence interval; OR: Odds Ratio. 
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Supplementary Figures 
 
Supplementary Figure S1. Relative binding of FVIII to VWF in the presence of anti-FVIII 
antibodies. Normal plasma (NP) was incubated with 100-fold molar excess of anti-factor VIII 
antibodies directed against A2 domain (BO2BII), C1 domain (LE2E9) and C2 domain (ESH8) 
VWF:FVIIIB was then assessed for NP alone or NP incubated with anti-FVIII antibodies 
(mean±SD).  
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Supplementary Figure S2. Effect of CaCl2 incubation in inhibitor-positive samples for severe 
HA patients (P1:6.5 BU/mL; P2: 20 BU/mL). A microplate was coated with rabbit polyclonal 
anti-human VWF IgG (5µg/mL). Plasma samples were then incubated in absence or presence 
of 350 mmol/L of CaCl2 to remove endogenous FVIII and immune complexes (FVIII with anti-
FVIII antibodies). (A) Following incubation, human IgG were detected using goat anti-human 
IgG antibody coupled with HRP. (B) Following incubation, bound VWF were revealed using 
polyclonal anti-VWF IgG coupled with HRP. 
 
